Literature DB >> 19720564

Reporter genes facilitating discovery of drugs targeting protozoan parasites.

Anuradha Dube1, Reema Gupta, Nasib Singh.   

Abstract

Transfection of protozoan parasites, such as Plasmodium, Leishmania, Trypanosoma and Toxoplasma, with various reporter gene constructs, has revolutionized studies to understand the biology of the host-parasite interactions at the cellular level. It has provided impetus to the development of rapid and reliable drug screens both for established drugs and for new molecules against different parasites and other pathogens. Furthermore, reporter genes have proved to be an excellent and promising tool for studying disease progression. Here, we review the recent advances made by using reporter genes for in vitro and in vivo drug screening, high-throughput screening, whole-animal non-invasive imaging for parasites and for the study of several aspects of host-parasite interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19720564     DOI: 10.1016/j.pt.2009.06.006

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  29 in total

1.  Methodological advances in drug discovery for Chagas disease.

Authors:  Juan M Bustamante; Rick L Tarleton
Journal:  Expert Opin Drug Discov       Date:  2011-06       Impact factor: 6.098

2.  In vitro screening test using Leishmania promastigotes stably expressing mCherry protein.

Authors:  Paola Vacchina; Miguel A Morales
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

3.  A Plasmodium falciparum strain expressing GFP throughout the parasite's life-cycle.

Authors:  Arthur M Talman; Andrew M Blagborough; Robert E Sinden
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

4.  An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.

Authors:  Marcele N Rocha; Célia M Corrêa; Maria N Melo; Stephen M Beverley; Olindo Assis Martins-Filho; Ana Paula Madureira; Rodrigo P Soares
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-10       Impact factor: 2.803

5.  A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.

Authors:  Diana Tegazzini; Rosario Díaz; Fernando Aguilar; Imanol Peña; Jesús L Presa; Vanessa Yardley; Julio J Martin; Jose M Coteron; Simon L Croft; Juan Cantizani
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds.

Authors:  Sonali Gangwar; Neena Goyal
Journal:  Curr Microbiol       Date:  2012-09-04       Impact factor: 2.188

7.  An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages.

Authors:  Jair L Siqueira-Neto; Seunghyun Moon; Jiyeon Jang; Gyongseon Yang; Changbok Lee; Hong Kee Moon; Eric Chatelain; Auguste Genovesio; Jonathan Cechetto; Lucio H Freitas-Junior
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

Review 8.  Imaging of the host/parasite interplay in cutaneous leishmaniasis.

Authors:  Owain R Millington; Elmarie Myburgh; Jeremy C Mottram; James Alexander
Journal:  Exp Parasitol       Date:  2010-05-23       Impact factor: 2.011

9.  Development of a Fluorescent Assay to Search New Drugs Using Stable tdTomato-Leishmania, and the Selection of Galangin as a Candidate With Anti-Leishmanial Activity.

Authors:  María Fernanda García-Bustos; Agustín Moya Álvarez; Cecilia Pérez Brandan; Cecilia Parodi; Andrea Mabel Sosa; Valeria Carolina Buttazzoni Zuñiga; Oscar Marcelo Pastrana; Paula Manghera; Pablo Alejandro Peñalva; Jorge Diego Marco; Paola Andrea Barroso
Journal:  Front Cell Infect Microbiol       Date:  2021-06-04       Impact factor: 5.293

10.  Stage-regulated GFP Expression in Trypanosoma cruzi: applications from host-parasite interactions to drug screening.

Authors:  Rafael Luis Kessler; Daniela Fiori Gradia; Rita de Cássia Pontello Rampazzo; Édio Elígio Lourenço; Nilson José Fidêncio; Lauro Manhaes; Christian Macagnan Probst; Andréa Rodrigues Ávila; Stenio Perdigão Fragoso
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.